Ariad Reaches New 52-Week High (ARIA)

NEW YORK ( TheStreet) -- Ariad Pharmaceuticals (Nasdaq: ARIA) hit a new 52-week high Friday as it is currently trading at $16.83, above its previous 52-week high of $16.75 with 1.4 million shares traded as of 11:15 a.m. ET. Average volume has been 3.4 million shares over the past 30 days.

Ariad has a market cap of $2.59 billion and is part of the health care sector and drugs industry. Shares are up 34.9% year to date as of the close of trading on Thursday.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.

TheStreet Ratings rates Ariad as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full Ariad Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)